ClinicalTrials.gg
CompletedNCT00128232Updated Apr 30, 2012

Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients

A Phase 3 interventional study of Octreotide LAR in Acromegaly, sponsored by Novartis. Completed. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2012-04-30.

Sponsored by Novartis · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing octreotide in Acromegaly — 1 open to participants now, 1 under way, 1 of them phase 3. Octreotide · Acromegaly.

Enrollment
6th of 25
100 · median 56
Started
2002
with 2 others
Phase 3
12 of 25
1 open now
Registered
3rd of 25
by date

Among the 25 studies testing octreotide in Acromegaly, this one is the 6th largest by enrollment, is one of 3 that started in 2002, is one of 12 in phase 3, and was the 3rd registered.

Acromegaly

202 studies on the registry are indexed under Acromegaly; 19 are open to participants now.

Browse Acromegaly studies →

Open to participants now

1 of the 25 studies testing octreotide in Acromegaly is open now. Recruiting first, the newest first:

About octreotide

Octreotide: first FDA approval 1988 (SANDOSTATIN), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 14 Acromegaly studies recruiting now, 7 (50%) set no upper age limit and 5 (36%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing octreotide in Acromegaly, or all of them as a file.
02

Study summary

Currently, the first line treatment for acromegaly is surgery, in order to remove the adenoma causing overproduction of growth hormone which leads to acromegaly. Octreotide LAR is approved for treatment of acromegaly after surgery if the disease is not controlled. This study was aimed to test the safety and efficacy of octreotide LAR in acromegalic patients who did not have any previous treatment for acromegaly.

03

Conditions studied

  • Acromegaly

Browse trials for

Keywords

  • Acromegaly
  • untreated
  • newly diagnosed
  • octreotide LAR
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newly diagnosed or previously untreated acromegalic patients
  • Lack of suppression of growth hormone (GH) nadir to \<1.0 µg/L, after oral administration of 75g of glucose (oral glucose tolerance test [OGTT])
  • Insulin-like growth factor-I (IGF-I) levels above the , i.e. 97th percentile (adjusted for age and gender)

Exclusion criteria

Exclusion Criteria:

  • Requires surgery for recent significant deterioration in visual fields or other neurological signs, which are related to the pituitary tumor mass
  • No evidence of pituitary adenoma on magnetic resonance imaging (MRI)
  • Symptomatic cholelithiasis
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Mean GH and IGF-I at baseline, week 12, 24 and 48

Secondary outcomes

  1. Tumor volume at baseline, week 24 and 48

  2. Signs and symptoms of acromegaly at baseline, week 12, 24 and 48

  3. Safety and tolerability at any time on treatment

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2002 and a primary completion of Aug 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2005
First posted
Aug 9, 2005
Start
Dec 2002
Primary completionActual
Aug 2004
Last update
Apr 30, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00128232
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
Aug 9, 2005
Start date
Dec 2002
Primary completion
Aug 2004
Last update
Apr 30, 2012

Study contacts

Stephan Petersenn, MD
principal investigator · Universität Duisburg-Essen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Octreotide

Start the discussion